Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel

Potential pathophysiological mechanisms in osteonecrosis of the jaw

(2011) Regina Landesberg et al.   Annals of the New York Academy of Sciences

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Docetaxel as a vital option for corticosteroid-refractory prostate cancer

(2011) Haruki Kume et al.   INTERNATIONAL UROLOGY AND NEPHROLOGY

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound

(2010) Jonathan R. Green et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate

(2008) Christian Walter et al.   EUROPEAN UROLOGY

Bisphosphonate-Related Osteonecrosis of the Jaws: A Case-Control Study of Risk Factors in Breast Cancer Patients

(2008) Athanassios Kyrgidis et al.   JOURNAL OF CLINICAL ONCOLOGY

Zoledronate, Smoking, and Obesity Are Strong Risk Factors for Osteonecrosis of the Jaw: A Case-Control Study

(2008) John H. Wessel et al.   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY